Answer
Spravato (esketamine hydrochloride), in combination with an SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder who have not responded to at least two different antidepressant treatments in the current moderate to severe depressive episode.
Sources for this answer
- Spravato 28 mg nasal spray, solutionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.1 Therapeutic Indications · Version 12Document updated
Sources checked